LAGUNA HILLS, CA -- (Marketwired) -- 07/31/13 -- Itonis, Inc. (PINKSHEETS: ITNS) and Charles Hensley, Ph.D., the inventor of the Zicam® cold remedy, are pleased to announce that the Company has received its labeler's code from the federal Food and Drug Administration (FDA).
The labeler's code is the company component of the National Drug Code (NDC) that identifies Itonis as the pharmaceutical company responsible for all of its homeopathic products.
Dr. Hensley commented, "We expect to receive the product component of the NDC for Emesyl from the FDA within the next few weeks."
Emesyl is Itonis' nausea relief product.
About Itonis Pharmaceuticals
Itonis Pharmaceuticals, a new division of Itonis, Inc., is headed by Charles Hensley, Ph.D. This division's mission is to create and market over-the-counter and prescription homeopathic products that better people's lives. Dr. Hensley is a pioneer in the development and marketing of safe and effective therapeutic nutraceutical and homeopathic preparations. He was a founder of the company that launched the Zicam® Cold Remedy, making the product a household name and forever changing the marketing and product placement paradigm for homeopathic drugs in the United States. Dr. Hensley and his team plan to use the same methodologies to revolutionize the treatment of several other common ailments and other chronic diseases.
About Itonis, Inc.
Itonis, Inc. was incorporated in the state of Nevada on July 5, 2005 under the name of Kenshou, Inc., which later changed to Itonis, Inc. on December 2, 2005. Please visit www.itonisholdings.com.
Statements in this press release may constitute forward-looking statements and are subject to numerous risks and uncertainties, including the failure to complete successfully the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's affiliates that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.
|Itonis Pharmaceuticals and Dr. Charles Hensley to Receive Delivery of First Production Batch of Emesyl(TM) Nausea Remedy ()|
|Itonis Pharmaceuticals and Dr. Charles Hensley Hitting Production Milestones for Protection of Emesyl(TM) Nausea Remedy (2013/11/18)|
|Itonis Pharmaceuticals to Conduct Case Study for Its Emesyl Brand of Nausea Remedy (2013/12/2)|
|Itonis Pharmaceuticals Completed Packaging Graphics for Its Emesyl Brand of Nausea Remedy ()|
|Itonis Pharmaceuticals to Trademark Emesyl Nausea Relief Remedy (2013/10/24)|
|Itonis Pharmaceuticals Received Emesyl Samples for Evaluation (2014/2/28)|
|Bristol-Myers Hepatitis C Treatment Receives FDA Breakthrough Therapy Status ()|
|Merrimack Pharmaceutical's MM-111 Granted Orphan Drug Status by FDA For Treatment of Advanced Gastric and Esophageal Cancers ()|
|FDA Awards Fast Track Status to Tetraphase Pharmaceuticals for IV and Oral Formulations of Eravacycline (2014/4/2)|
|Catalyst Pharmaceutical Partners Receives Breakthrough Therapy Designation From FDA for Firdapse(TM) for the Treatment of LEMS ()|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.